Impact of cannabis use on thalamic volume in people at familial high risk of schizophrenia

British Journal of Psychiatry

Volumn 199, Issue 5, 2011, Pages 386-390

  Welch, Killian A ^a,b   Stanfield, Andrew C ^b   McIntosh, Andrew M ^b   Whalley, Heather C ^b   Job, Dominic E ^b   Moorhead, Thomas W ^b   Owens, David G C ^b   Lawrie, Stephen M ^b   Johnstone, Eve C ^b  

^a ASTLEY AINSLIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BRAIN SIZE; FEMALE; GENETIC RISK; HIGH RISK POPULATION; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SCHIZOPHRENIA; THALAMUS;

ADOLESCENT; ADULT; AMYGDALA; ANALYSIS OF VARIANCE; CANNABIS; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; RISK FACTORS; SCHIZOPHRENIA; THALAMUS; TIME FACTORS; YOUNG ADULT;

EID: 80655148022     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.090175     Document Type: Article

References (40)

1. Crespo-Facorro B, Roiz-Santiáñez R, Pelayo-Terán JM, Rodríguez-Sánchez JM, Pérez-Iglesias R, González-Blanch C, et al. Reduced thalamic volume in first-episode non-affective psychosis: correlations with clinical variables, symptomatology and cognitive functioning. Neuroimage 2007; 35: 1613-23. (Pubitemid 46562573)
2. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52. (Pubitemid 32451739)
3. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184: 110-7. (Pubitemid 38186851)
4. Martín-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, et al. Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 2010; 40: 383-98.
5. Rais M, Cahn W, Van Haren N, Schnack H, Caspers E, Hulshoff Pol H, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008; 165: 490-6. (Pubitemid 351694292)
6. Welch KA, McIntosh AM, Job DE, Whalley HC, Moorhead TW, Hall J, et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. Schizophr Bull 2010; Mar 11. Epub ahead of print.
7. Hodges A, Byrne M, Grant E, Johnstone E. People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Br J Psychiatry 1999; 174: 547-53. (Pubitemid 29278690)
8. Lawrie SM, Whalley HC, Abukmeil SS, Kestelman JN, Donnelly L, Miller P, et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry 2001; 49: 811-23. (Pubitemid 32436386)
9. McDonald C, Bullmore E, Sham P, Chitnis X, Suckling J, MacCabe J, et al. Regional volume deviations of brain structure in schizophrenia and psychotic bipolar disorder. Computational morphometry study. Br J Psychiatry 2005; 186: 369-77. (Pubitemid 40663418)
10. McIntosh AM, Job DE, Moorhead WJ, Harrison LK, Whalley HC, Johnstone EC, et al. Genetic liability to schizophrenia or bipolar disorder and its relationship to brain structure. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 76-83. (Pubitemid 43062547)
11. Chan RCK, Di X, McAlonan GM, Gong Q. Brain anatomical abnormalities in high-risk individuals, first-episode, and chronic schizophrenia: an activation likelihood estimation meta-analysis of illness progression. Schizophr Bull 2011; 37: 177-88.
12. Svíženská I, Dubový P, Šulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures: a short review. Pharmacol Biochem Behav 2008; 90: 501-11.
13. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res 2001; 49: 1-52. (Pubitemid 32451739)
14. Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR. Marijuana intoxication and brain activation in marijuana smokers. Life Sci 1997; 60: 2075-89. (Pubitemid 27239657)
15. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26: 802-16. (Pubitemid 34455033)
16. Freedland CS, Whitlow CT, Miller MD, Porrino LJ. Dose-dependent effects of Δ9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 2002; 45: 134-42. (Pubitemid 34742949)
17. Lawrie SM, McIntosh AM, Hall J, Owens DGC, Johnstone EC. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008; 34: 330-40. (Pubitemid 351323338)
18. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 2007; 17: 175-91. (Pubitemid 44973906)
19. Whalley HC, Kestelman JN, Rimmington JE, Kelso A, Abukmeil SS, Best JJK, et al. Methodological issues in volumetric magnetic resonance imaging of the brain in the Edinburgh High Risk Project. Psychiatr Res 1999; 91: 31-44. (Pubitemid 30074181)
20. Lawrie SM, Whalley HC, Abukmeil SS, Kestelman JN, Donnelly L, Miller P, et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry 2001; 49: 811-23.
21. de Win MML, Jager G, Booij J, Reneman L, Schilt T, Lavini C, et al. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry 2008; 193: 289-96.
22. Rust J. The Rust Inventory of Schizotypal Cognitions (RISC). Schizophr Bull 1988; 14: 317-22.
23. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51: 273-9. (Pubitemid 24127299)
24. Zammit S, Moore THM, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry 2008; 193: 357-63.
25. Byne W, Hazlett EA, Buchsbaum MS, Kemether E. The thalamus and schizophrenia: current status of research. Acta Neuropathol 2009; 117: 347-68.
26. Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci 1995; 3: 89-97.
27. Andreasen NC, Paradiso S, O'Leary DS. 'Cognitive dysmetria' as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical- cerebellar circuitry? Schizophr Bull 1998; 24: 203-18. (Pubitemid 28404981)
28. Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry 1999; 46: 908-20. (Pubitemid 29452982)
29. Whalley HC, Simonotto E, Flett S, Marshall I, Ebmeier KP, Owens DGC, et al. fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain 2004; 127: 478-90. (Pubitemid 38295466)
30. Byrne M, Hodges A, Grant E, Owens DC, Johnstone EC. Neuropsychological assessment of young people at high genetic risk for developing schizophrenia compared with controls: preliminary findings of the Edinburgh High Risk Study (EHRS). Psychol Med 1999; 29: 1161-73. (Pubitemid 29469306)
31. O'Connor M, Harris JM, McIntosh AM, Owens DGC, Lawrie SM, Johnstone EC. Specific cognitive deficits in a group at genetic high risk of schizophrenia. Psychol Med 2009; 39: 1649-55.
32. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 1990; 16: 425-32.
33. Jones EG. Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 1997; 23: 483-501.
34. Mega MS, Cummings JL. Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6: 358-70. (Pubitemid 24344856)
35. Coscia DM, Narr KL, Robinson DG, Hamilton LS, Sevy S, Burdick KE, et al. Volumetric and shape analysis of the thalamus in first-episode schizophrenia. Hum Brain Mapp 2009; 30: 1236-45.
36. Lawrie SM, Whalley HC, Abukmeil SS, Kestelman JN, Miller P, Best JJK, et al. Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. Br J Psychiatry 2002; 181: 138-43. (Pubitemid 34864496)
37. Harms MP, Wang L, Mamah D, Barch DM, Thompson PA, Csernansky JG. Thalamic shape abnormalities in individuals with schizophrenia and their nonpsychotic siblings. J Neurosci 2007; 27: 13835-42. (Pubitemid 350278275)
38. Cronenwett WJ, Csernansky J. Thalamic pathology in schizophrenia. In Behavioral Neurobiology of Schizophrenia and Its Treatment (eds DA Kendall, S Alexander): 509-28. Springer-Verlag, 2010.
39. Young KA, Manaye KF, Liang CL, Hicks PB, German DC. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol Psychiatry 2000; 47: 944-53. (Pubitemid 30320739)
40. Sim K, Cullen T, Ongur D, Heckers S. Testing models of thalamic dysfunction in schizophrenia using neuroimaging. J Neural Transm 2006; 113: 907-28. (Pubitemid 43962784)